Fulcrum Therapeutics price to sales ratio FULC

Market value divided by revenue over the last twelve months, since 2021.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 5.3×; Jul 2025
6-year median: 27.9×
6-year range: 1.7× to 198×
Peer median: 1.5×

Fulcrum Therapeutics' price to sales ratio is not a meaningful number today: revenue for one or more of the four quarters through 2026-06-30 is missing, so twelve months can't be added up.

It was last meaningful in Jul 2025, at 5.3×.

On the days it had one over the last 6 years, its median was 27.9×, from 1.7× in Apr 2025 to 198× in Jul 2024.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2025	5.3×	1.7×	5.3×
2024	3.2×	2.0×	198×
2023	159×	23.2×	159×
2022	35.4×	11.1×	50.3×
2021	39.1×	18.6×	66.2×

Against its peers

Companies in Drug Manufacturers - General nearest Fulcrum Therapeutics' size, closest first, today.

Company	Price to sales ratio
FULCFulcrum Therapeutics	n/m
NATRNatures Sunshine Products	0.4×
ARVNArvinas	1.5×
PBYIPuma Biotechnology	2.5×
IRWDIronwood Pharmaceuticals	1.5×
ZVRAZevra Therapeutics	4.3×
CRMDCorMedix	1.3×
COLLCollegium Pharmaceutical	0.9×
ABUSArbutus Biopharma	4.6×
AMPHAmphastar Pharmaceuticals	1.5×
LFVNLifevantage	0.4×
Peer median	1.5×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Fulcrum Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.